Pharma BD Deal Intelligence

Eli Lilly and Company / Curevo Vaccine, Inc.

2026 · Acquisition/Merger · $1.5B · Pending

Eli Lilly agreed to acquire Seattle-area Curevo Vaccine for up to $1.5B (upfront plus single specified milestone). Curevo's lead candidate amezosvatein is an adjuvanted subunit shingles vaccine with Phase 2 data showing immune response matching standard-of-care Shingrix and >50% reductions in fatigue, chills and injection-site pain. Part of Lilly's three-deal vaccine push into infectious disease announced same day.

Key facts

• Announced May 26, 2026
• Deal value $1.5B
• Deal type Acquisition/Merger
• Therapeutic area Herpes zoster (shingles) prevention in adults
• Indications Herpes zoster (shingles) prevention in adults
• Key assets amezosvatein (adjuvanted subunit varicella zoster virus / shingles vaccine)
• Mechanism Recombinant gE subunit adjuvanted vaccine eliciting humoral and cellular immunity against VZV

← Browse all deals  ·  How we score deals